Market expert Sandip Sabharwal maintains a constructive long-term outlook but stresses selectivity due to near-term risks like rising input costs and competition. He favors midcaps and selective smallcaps, seeing opportunities in consumer durables, while cautioning on financials and quick commerce. Large pharma deals require careful integration and valuation assessment.
HFCL shares rally 4% after Rs 495-crore order win. Should you buy after 200% surge in 2026?
HFCL shares witnessed an uptick on Friday after the company secured a Rs 496 crore overseas order for data centre connectivity solutions, extending their 220%